viewPreveCeutical Medical Inc.

PreveCeutical Medical joins forces with Asterion Cannabis to develop CBD products

The development agreement has an initial term of two years, renewable by the parties for an additional two-year term

The company is trying to improve global health via natural products

Health sciences group PreveCeutical Medical Inc (CNSX:PREV) told investors it had struck a deal with private pot firm Asterion Cannabis Inc to develop medical CBD (cannabidiol) products.

In the companies’ sights via the joint venture are tablets, transdermal patches and other jointly evaluated products aimed at treating chronic pain, inflammation, epilepsy,  anxiety disorders and others.

Stephen Van Deventer, the group's chairman and chief executive, said the latest deal further supported the company's mission to improve global health and health care via natural products.

"Our joint venture with Asterion comes at an important time, using Asterion's high-quality, low-cost, genetically uniform strains of medicinal cannabis will allow Preveceutical to supply the anticipated increasing demand for effective and personalised cannabis-based therapies."

Any cash needed by the joint venture will be financed 100% by Asterion, at cost.

Asterion will contribute industry knowledge and contacts to the joint venture, while Preveceutical will be providing access to its research team and the resources.

Any intellectual property (IP) and products developed by the joint venture during its term will be owned by Asterion and Preveceutical 80%: 20% respectively.

The development agreement has an initial term of two years, renewable by the parties for an additional two-year term.

Preveceutical will receive 20% of the net revenue earned or proceeds received by the joint venture from the sale of the IP and products developed by the joint venture.

Quick facts: PreveCeutical Medical Inc.

Price: 0.04 CAD

Market: CSE
Market Cap: $19.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read